175 related articles for article (PubMed ID: 37047588)
21. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology.
Agoulnik IU; Kaftanovskaya EM; Myhr C; Bathgate RAD; Kocan M; Peng Y; Lindsay RM; DiStefano PS; Agoulnik AI
Biochem Pharmacol; 2024 Jun; ():116401. PubMed ID: 38945278
[TBL] [Abstract][Full Text] [Related]
22. The minimal active structure of human relaxin-2.
Hossain MA; Rosengren KJ; Samuel CS; Shabanpoor F; Chan LJ; Bathgate RA; Wade JD
J Biol Chem; 2011 Oct; 286(43):37555-65. PubMed ID: 21878627
[TBL] [Abstract][Full Text] [Related]
23. Characterizing relaxin receptor expression and exploring relaxin's effect on tissue remodeling/fibrosis in the human bladder.
Diaz EC; Briggs M; Wen Y; Zhuang G; Wallace SL; Dobberfuhl AD; Kao CS; Chen BC
BMC Urol; 2020 Apr; 20(1):44. PubMed ID: 32321501
[TBL] [Abstract][Full Text] [Related]
24. Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone.
Shabanpoor F; Bathgate RA; Belgi A; Chan LJ; Nair VB; Wade JD; Hossain MA
Biochem Biophys Res Commun; 2012 Apr; 420(2):253-6. PubMed ID: 22425984
[TBL] [Abstract][Full Text] [Related]
25. The roles of the A- and B-chains of human relaxin-2 and -3 on their biological activity.
Hossain MA; Wade JD
Curr Protein Pept Sci; 2010 Dec; 11(8):719-24. PubMed ID: 21235507
[TBL] [Abstract][Full Text] [Related]
26. Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists.
Granberg KL; Sakamaki S; Fuchigami R; Niwa Y; Fujio M; Kato H; Bergström F; Larsson N; Persson M; Villar IC; Fujita T; Sugikawa E; Althage M; Yano N; Yokoyama Y; Kimura J; Lal M; Mochida H
J Med Chem; 2024 Mar; 67(6):4442-4462. PubMed ID: 38502780
[TBL] [Abstract][Full Text] [Related]
27. The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors.
Hossain MA; Rosengren KJ; Haugaard-Jönsson LM; Zhang S; Layfield S; Ferraro T; Daly NL; Tregear GW; Wade JD; Bathgate RA
J Biol Chem; 2008 Jun; 283(25):17287-97. PubMed ID: 18434306
[TBL] [Abstract][Full Text] [Related]
28. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
29. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.
Alam F; Gaspari TA; Kemp-Harper BK; Low E; Aw A; Ferens D; Spizzo I; Jefferis AM; Praveen P; Widdop RE; Bathgate RAD; Hossain MA; Samuel CS
Biomed Pharmacother; 2023 Apr; 160():114370. PubMed ID: 36753958
[TBL] [Abstract][Full Text] [Related]
30. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist.
Hossain MA; Samuel CS; Binder C; Hewitson TD; Tregear GW; Wade JD; Bathgate RA
Amino Acids; 2010 Jul; 39(2):409-16. PubMed ID: 20043231
[TBL] [Abstract][Full Text] [Related]
31. Inhaled B7 alleviates bleomycin-induced pulmonary fibrosis in mice.
Liu Y; Wang S; Gong X; Wang Y; Xu T
Bioorg Med Chem; 2021 Nov; 50():116482. PubMed ID: 34757292
[TBL] [Abstract][Full Text] [Related]
32. The complex binding mode of the peptide hormone H2 relaxin to its receptor RXFP1.
Sethi A; Bruell S; Patil N; Hossain MA; Scott DJ; Petrie EJ; Bathgate RAD; Gooley PR
Nat Commun; 2016 Apr; 7():11344. PubMed ID: 27088579
[TBL] [Abstract][Full Text] [Related]
33. Probing the functional domains of relaxin-3 and the creation of a selective antagonist for RXFP3/GPCR135 over relaxin receptor RXFP1/LGR7.
Liu C; Kuei C; Sutton S; Shelton J; Zhu J; Nepomuceno D; Hossain MA; Wade JD; Bathgate RA; Bonaventure P; Lovenberg T
Ann N Y Acad Sci; 2009 Apr; 1160():31-7. PubMed ID: 19416155
[TBL] [Abstract][Full Text] [Related]
34. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.
Devarakonda T; Mauro AG; Guzman G; Hovsepian S; Cain C; Das A; Praveen P; Hossain MA; Salloum FN
J Am Heart Assoc; 2020 Apr; 9(8):e015748. PubMed ID: 32295457
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of fluorescent analogs of relaxin family peptides and their preliminary in vitro and in vivo characterization.
Chan LJ; Smith CM; Chua BE; Lin F; Bathgate RA; Separovic F; Gundlach AL; Hossain MA; Wade JD
Front Chem; 2013; 1():30. PubMed ID: 24790958
[TBL] [Abstract][Full Text] [Related]
36. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and characterization of a single-chain peptide antagonist for the relaxin-3 receptor RXFP3.
Haugaard-Kedström LM; Shabanpoor F; Hossain MA; Clark RJ; Ryan PJ; Craik DJ; Gundlach AL; Wade JD; Bathgate RA; Rosengren KJ
J Am Chem Soc; 2011 Apr; 133(13):4965-74. PubMed ID: 21384867
[TBL] [Abstract][Full Text] [Related]
38. Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease.
Samuel CS; Royce SG; Chen B; Cao H; Gossen JA; Tregear GW; Tang ML
Endocrinology; 2009 Mar; 150(3):1495-502. PubMed ID: 18974264
[TBL] [Abstract][Full Text] [Related]
39. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
